AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
Two highly anticipated Presidential Symposia for TROPION-Lung01 and TROPION-Breast01 will unveil the significance of datopotamab deruxtecan in lung and breast cancers. FLAURA2 data reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer and underscore its added benefit of treating brain metastases. DUO-E results for Imfinzi plus Lynparza will show the benefit of immunotherapy and PARP inhibitor combinations in endometrial cancer for the first time. First Imfinzi data in gastric cancer from MATTERHORN Phase III trial will highlight the potential of immunotherapy combinations